Imatinib pregnancies
| Pregnancy outcome . | Timing of exposure in pregnancy by trimester, no. of patients . | |||||
|---|---|---|---|---|---|---|
| Before LMP . | First trimester . | After first trimester . | Throughout pregnancy . | Unknown . | Subtotal . | |
| Spontaneous abortion | 0 | 8 | 0 | 7 | 3 | 18 |
| Elective termination | ||||||
| Fetal defects | 0 | 1 | 0 | 1* | 1 | 3 |
| Normal or unknown | 0 | 20 | 0 | 5 | 7 | 32 |
| Stillbirth with fetal defects | 0 | 1 | 0 | 0 | 0 | 1 |
| Live birth with congenital anomaly | 0 | 6 | 0 | 0 | 2 | 8 |
| Live birth without congenital anomaly | 0 | 40† | 1 | 18 | 4 | 63 |
| Outcome unknown | 1 | 27 | 3 | 7 | 17 | 55 |
| Total | 1 | 103 | 4 | 38 | 34 | 180 |
| Pregnancy outcome . | Timing of exposure in pregnancy by trimester, no. of patients . | |||||
|---|---|---|---|---|---|---|
| Before LMP . | First trimester . | After first trimester . | Throughout pregnancy . | Unknown . | Subtotal . | |
| Spontaneous abortion | 0 | 8 | 0 | 7 | 3 | 18 |
| Elective termination | ||||||
| Fetal defects | 0 | 1 | 0 | 1* | 1 | 3 |
| Normal or unknown | 0 | 20 | 0 | 5 | 7 | 32 |
| Stillbirth with fetal defects | 0 | 1 | 0 | 0 | 0 | 1 |
| Live birth with congenital anomaly | 0 | 6 | 0 | 0 | 2 | 8 |
| Live birth without congenital anomaly | 0 | 40† | 1 | 18 | 4 | 63 |
| Outcome unknown | 1 | 27 | 3 | 7 | 17 | 55 |
| Total | 1 | 103 | 4 | 38 | 34 | 180 |
The table Shows the outcome data for 180 pregnancies occurring in women receiving imatinib. It includes 4 women treated with imatinib for gastrointestinal stromal tumors (GISTs), 28 treated for unknown indications, and 5 treated for miscellaneous conditions. The data were collected by Novartis Pharmaceuticals (Basel, Switzerland).
LMP indicates last menstrual period.
Mother had concomitantly been receiving warfarin therapy. The results of a subsequent postmortem revealed defects typical of warfarin embryopathy.
Includes 4 patients with exposure in both first and second trimesters.